Related Experiment Video
Updated: Aug 5, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose
Roberto Mina1, Evangelos Terpos2, Lorenzo Cani3
1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
Clinical Lymphoma, Myeloma & Leukemia
|July 28, 2026
Summary
Belantamab mafodotin combinations significantly improved response rates in relapsed/refractory multiple myeloma. While ocular side effects occur, they are manageable and reversible, allowing for optimized treatment strategies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
- It is used for relapsed or refractory multiple myeloma.
Purpose of the Study:
- To review the efficacy and safety of belantamab mafodotin, focusing on ocular toxicity.
- To discuss strategies for managing ocular adverse events and optimizing dosing.
Main Methods:
- Review of current literature on belantamab mafodotin.
- Analysis of data from DREAMM-7 and DREAMM-8 phase III trials.
Main Results:
- Belamaf combinations with bortezomib-dexamethasone or pomalidomide-dexamethasone showed superior response rates and measurable residual disease negativity compared to standard care.
- Ocular adverse events (AEs) are common but reversible and rarely lead to discontinuation.
- Regulatory approvals have been granted for belamaf combinations.
Conclusions:
- Belantamab mafodotin-based regimens are effective treatment options for relapsed/refractory multiple myeloma.
- Management strategies for ocular toxicity are crucial for maximizing therapeutic benefit.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...